All In Biotech

Drug Trial Radar · NCT07748624

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Dec 26, 2028

Study completion Apr 15, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.

Conditions

  • VEXAS Syndrome

Interventions

  • ArumakimigDrug

    Arumakimig Injection

  • PlaceboDrug

    Placebo Injection

  • Oral glucocorticoidsDrug

    Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid (GC) reduction at Week 52Time frame: From baseline up to Week 52

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Fukushima, Japan · Recruiting

  • Novartis Investigative Site

    Niigata, Japan · Recruiting

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan · Recruiting

  • Novartis Investigative Site

    Suita, Osaka, Japan · Recruiting

  • Novartis Investigative Site

    Hachiōji, Tokyo, Japan · Recruiting

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.